SEC Form 4 · accession 0000950138-18-000055
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Trudeau
Officer — President and CEO · Director
Period of report
Jan 3, 2018
Accepted (ET)
Jan 5, 2018 · 7:44 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Jan 3, 2018 | F | 4,370 | $23.51 | D | 268,543 | D | |
| Ordinary Shares | Jan 4, 2018 | F | 2,644 | $23.40 | D | 265,899 | D |
Table II — derivative securities
No Table II lines on this filing.
Remarks
This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.